<DOC>
	<DOCNO>NCT01010399</DOCNO>
	<brief_summary>In subject boosted protease inhibitor ( PI ) -regimens elevated triglyceride , switch fosamprenavir/ritonavir daily follow addition Lovaza result 30 % patient achieve reduction fast triglyceride &lt; 200 mg /dL maintain virologic suppression .</brief_summary>
	<brief_title>Boosted Lexiva With Lovaza Adjunctive Therapy Hypertriglyceridemic , HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>fast triglyceride &gt; = 200 mg/dL &lt; 1,200 mg/dL fast LDL &lt; = 160 mg/dL participation lipidlowering diet exercise program least 28 day treatment stable HAART consist first second RTVboosted PI regimen plus optimized background ART least 3 month plasma HIV1 RNA &lt; 50 copies/mL CD4+ cell count &gt; 50 cells/mm3 male subjection testosterone replacement therapy total testosterone level &lt; = 1 x upper limit normal female study volunteer must use form contraception ability willing ness give write informed consent Grade 4 laboratory abnormality currently take amprenavir fosamprenavir require second RTVboosted PI reason virologic failure atherosclerotic disease risk congestive heart failure ( NYHA Class III IV ) uncontrolled hypertension history pancreatitis active bleeding disorder recent history significant renal , pulmonary , biliary , hepatic gastrointestinal disease current diabetes mellitus require pharmacological treatment use systemic cancer chemotherapy ; active cancer pregnancy breastfeed requirement lipidlowering agent baseline use hormonal anabolic therapy , systemic steroid , immune modulators use anticoagulant , investigational antiretroviral drug allergy study drug active CDC clinical category C event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>triglyceride</keyword>
	<keyword>fosamprenavir</keyword>
</DOC>